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TO THE EDITOR
Once cutaneous melanoma metastasizes
prognosis of patients is generally poor in
spite of recent therapeutic advances.
Prognostic biomarkers are needed to
better identify those patients with primary
melanoma who are at increased risk of
metastatic disease. Gene expression sig-
natures have been deﬁned that are
associated with metastatic capacity of
primary melanoma and survival
(Winnepenninckx et al., 2006; Conway
et al., 2009). Genomic characterization
has revealed diverse recurrent genetic
alterations including those that drive the
tumorigenic process. However, the
underlying molecular changes that
confer the capacity to melanoma cells
to migrate and colonize distant body sites
remain to be deﬁned. Promoter CpG
island hypermethylation constitutes a
mechanism responsible for deregu-
lated expression of genes involved in
metastasis. We and others have identi-
ﬁed epigenetic alterations in melanoma
affecting genes with a potential role in
tumor cell dissemination including
CDH11 and SERPINB5 (Carmona et al.,
2012; Gao et al., 2013; Dahl et al., 2015).
In addition, a 17-gene methylation signa-
ture was found to predict disease course
of stage IIIC melanoma patients (Sigalotti
et al., 2012). As epigenetic biomarker for
metastasis, promoter hypermethylation
has the advantage that it is stable and
can be reliably detected in clinical
samples. The purpose of this study was
to identify methylation events that can
predict the development of lethal
metastatic disease in patients with
primary cutaneous melanoma.
To this end, we collected clinical
follow-up data of 24 patients with
primary melanoma whose tumors had
been previously subjected to genome-
wide DNA methylation proﬁling using
Illumina 27 K arrays, analyzing methy-
lation of 14 495 genes (Gao et al.,
2013). Thirteen patients had developed
distant metastases, all of whom died
because of melanoma, and in 11
patients no metastatic dissemination or
tumor recurrence had been detected
during a follow-up period of at least 6
years after diagnosis. We compared
methylation proﬁles from primary
melanomas of patients who developed
lethal distant organ metastasis (M+)
with those from primary melanomas of
patients who had not developed metas-
tasis (M− ). CpG probes with an
average β-value difference (a measure
of differential DNA methylation reﬂect-
ing ﬂuorescence intensity ratios
between methylated and unmethylated
alleles) higher than 0.20 between M+
and M− primary melanomas were
considered indicative of hypermethyla-
tion of the corresponding gene promo-
ter region. This re-analysis yielded six
candidate hypermethylated genes in
melanoma with metastatic behavior
(M+): MCHR1, SYNPO2, C1orf106,
HIST1H3G, ZNF35, and GNMT
(Figure 1a). We did not ﬁnd genes
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Figure 1. Differential promoter methylation in primary melanomas with different metastatic outcome.
(a) Methylation proﬁles of primary melanomas from patients who developed lethal distant organ
metastasis (M+, n=13) were compared with those from patients who had not developed metastasis
(M− , n=11), yielding six genes with average β-value difference higher than 0.20. (b) Synaptopodin 2
(SYNPO2) ampliﬁcation products from methylation-speciﬁc polymerase chain reaction (MSP) are shown
for two M− primary melanomas and three M+ primary melanomas. ctrl+, positive control (lymphocyte
DNA treated with Sss1 methyltransferase); ctrl− , negative control (DNA from human umbilical vein
endothelial cells); H2O(1), no template control for ﬁrst ampliﬁcation with ﬂanking primers; H2O(2), no
template control for second ampliﬁcation with primers speciﬁc for methylated and unmethylated DNA;
m, methylated; u, unmethylated.
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Abbreviations: C1orf106, chromosome 1 open reading frame 106; FFPE, formalin-ﬁxed parafﬁn-
embedded; GNMT, glycine N-methyltransferase; HIST1H3G, histone cluster 1 H3g; MCHR1, melanin-
concentrating hormone receptor 1; SYNPO2, synaptopodin 2; ZNF35, zinc-ﬁnger protein 35
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hypomethylated in melanoma with
metastatic behavior. Validation of these
six genes in an independent series of 20
fresh-frozen M+ primary melanomas
and 25 M− primary melanomas using
bisulphite melting curve analysis
showed promoter hypermethylation of
MCHR1 and SYNPO2 to be associated
with metastatic behavior (Supplemen-
tary Table S1 online). We proceeded
with promoter methylation analysis of
MCHR1 and SYNPO2 in an indepen-
dent series of 113 formalin-ﬁxed
parafﬁn-embedded (FFPE) primary
invasive cutaneous melanoma samples
with available melanoma-speciﬁc survi-
val data using methylation-speciﬁc PCR
(Supplementary Table S2a–c online
and Supplementary Materials and
Methods online). This demonstrated for
the MCHR1 promoter a gradual but not
absolute methylation difference
between metastatic and non-metastatic
melanoma samples, limiting its use as a
prognostic biomarker. There was a
marked difference in SYNPO2 promoter
methylation between metastatic and
non-metastatic melanomas (Figure 1b).
Primary melanomas with SYNPO2
promoter hypermethylation had a sig-
niﬁcantly shorter survival (hazards ratio
for melanoma-related death 2.01, 95%
conﬁdence interval 1.06–3.82; Po0.034
in univariate analysis) (Figure 2a).
Importantly, SYNPO2 promoter hyper-
methylation remained a statistically sig-
niﬁcant prognostic factor after adjusting
for tumor thickness (hazards ratio for
melanoma-related death 2.02, 95% con-
ﬁdence interval 1.05–3.89, Po0.034 in
multivariate analysis) (Supplementary
Table S3 online). When considering
tumor thickness, age (as continuous
variables), gender, and ulceration as
covariates in multivariate analysis, still
an association of SYNPO2 methylation
and reduced melanoma-speciﬁc survival
was observed that did not reach statis-
tical signiﬁcance in this sample series.
SYNPO2 promoter methylation was
shown to associate with transcriptional
repression (Cebrian et al., 2008).
Demethylation using 5-aza-2′-deoxy-
cytidine of three SYNPO2-methylated
melanoma cell lines resulted in
reactivation of expression in treated
cells, providing evidence for a link
between promoter methylation and
transcription regulation in melanoma
(Figure 2b, Supplementary Figure S1
online). To examine whether SYNPO2
gene expression levels provided
prognostic information and to support
a role for epigenetic silencing of this
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Figure 2. Synaptopodin 2 (SYNPO2) promoter methylation and expression status are associated with
survival outcome. (a) Kaplan–Meier estimate of survival function for melanoma-related death by SYNPO2
promoter methylation status was calculated and plotted against TTDOLC (time until dead or last contact). Gray
line, primary melanomas scored as negative for SYNPO2 promoter methylation using methylation-speciﬁc
polymerase chain reaction (MSP); black line, primary melanomas scored as positive. Po0.05 from the Log
rank test was considered signiﬁcant. (b) Relative SYNPO2 mRNA expression in melanoma cell lines WM35,
WM3248, and 530 treated with either mock or 5 μM 5-aza-2′-deoxycytidine for 96 hours. Expression levels
were analyzed in duplicate. *Po0.05; **Po0.01. (c) Kaplan–Meier estimate of survival function for
melanoma-related death by probe ILMN_1688220 measuring SYNPO2 expression in 202 primary melanomas
from the Leeds Melanoma cohort. Gray line, primary melanomas with high SYNPO2 expression; black line,
primary melanomas with low SYNPO2 expression. Po0.05 from the Log rank test was considered signiﬁcant.
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gene in acquisition of metastatic beha-
vior, we investigated its expression
in 202 primary melanomas from the
Leeds Melanoma cohort and tested
correlation with melanoma-speciﬁc sur-
vival (Supplementary Table S2d online)
(Conway et al., 2009; Jewell et al.,
2015). Illumina DASL HT12 v4 arrays
were used to measure whole-genome
gene expression in FFPE tumors and
after quantile normalization melanoma-
speciﬁc survival analysis was con-
ducted (Supplementary Materials and
Methods online). Two SYNPO2 probes
were available on the DASL array
(ILMN_1688220 and ILMN_1730218).
The association of low expression
with shorter melanoma-speciﬁc survival
was statistically signiﬁcant for
ILMN_1688220 before and after adjust-
ing for age, gender, and tumor thickness
in Cox proportional hazards regression
(hazards ratio for melanoma-related
death 2.04, 95% conﬁdence interval
1.08–3.85, Po0.04) (Figure 2c,
Supplementary Table S4 online). The
ILMN_1730218 probe showed a
similar trend in association with
melanoma-speciﬁc survival, although it
did not reach statistical signiﬁcance
after adjusting for these covariates
(Supplementary Table S4 online). The
gene expression data are therefore
consistent with an association bet-
ween SYNPO2 silencing by promoter
methylation and shorter survival.
SYNPO2 has multiple isoforms, which
may explain a weaker association
found for one of the probes (De Ganck
et al., 2008). Summarizing, SYNPO2
hypermethylation and diminished expre-
ssion are associated with shorter
melanoma-speciﬁc survival. Prognostic
signiﬁcance of SYNPO2 hypermethyla-
tion and gene expression is independent
of tumor thickness.
In line with our observations in
melanoma, SYNPO2 methylation was
found to associate with tumor aggres-
siveness and poor clinical outcome in
patients with bladder and colon cancer
(Alvarez-Mugica et al., 2010; Esteban
et al., 2012). In aggressive prostate
cancer, the locus on chromosome 4q26
harboring SYNPO2 is frequently deleted
(Lin et al., 2001). SYNPO2 encodes
myopodin, a member of the synapto-
podin family of actin-binding proteins
that regulate cell shape and motility.
In prostate cancer cells, myopodin
inhibits tumor growth and invasion
in vitro and in vivo (Jing et al., 2004).
The ability of myopodin to inhibit tumor
cell migration depends on its binding to
zyxin and integrin-link kinase (Yu and
Luo, 2006, 2011). It is thought that
myopodin primarily affects cell migra-
tion and invasion by inducing changes
in actin cytoskeleton networks (Kai and
Duncan, 2013). The potential involve-
ment of myopodin in melanoma cell
dissemination deserves further exami-
nation. The clinical value of SYNPO2
methylation in predicting metastatic
behavior of primary melanoma should
be addressed in larger prospective
studies, possibly combined with other
candidate epigenetic markers.
Collection, storage and use of all
tissues and patient data were performed
in agreement with the “Code for Proper
Secondary Use of Human Tissue in
the Netherlands”. Patient consent
for experiments was not required
because French laws consider human
tissue left over from surgery as dis-
carded material.
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Adiponectin Deﬁciency Contributes to Sensitivity in
Human Skin
Journal of Investigative Dermatology (2015) 135, 2331–2334; doi:10.1038/jid.2015.150; published online 14 May 2015
TO THE EDITOR
Sensitive skin is deﬁned as an exagger-
ated reaction to environmental factors,
characterized by prickling, burning,
itching, stinging, pain, or tingling sensa-
tion (Berardesca et al., 2006; Farage and
Maibach, 2010). Recently, in addition
to a previous notion that sensitive skin is
associated with increased neurosensory
responses, impaired skin barrier funct-
ion, and altered immune responsiveness
(Ständer et al., 2009), we discovered
that sensitive skin is closely associated
with the dysfunction of muscle contrac-
tion, carbohydrate and lipid metabo-
lism, and ion balance, by using an
unbiased microarray analysis of skin
samples obtained from subjects with
sensitive or non-sensitive skin (Kim
et al., 2014). However, the critical regu-
lator implicated in the pathogenesis of
sensitive skin remains still elusive.
Previous microarray ﬁndings suggest
that adiponectin (ADIPOQ) is one of the
downregulated genes in sensitive skin
(Kim et al., 2014). ADIPOQ is an
adipocyte-derived adipokine with multi-
ple salutary effects such as anti-apopto-
tic, anti-inﬂammatory, and anti-oxidative
activities, as well as anti-obesity and
anti-insulin resistance roles in diverse
organs and cells including skeletal mus-
cles, liver, and adipose tissues (Goldstein
and Scalia, 2004). Particularly, ADIPOQ
is known to regulate muscle phenotypes
and functions (Krause et al., 2008).
ADIPOQ induces vascular smooth
muscle cell differentiation, suppresses
triglyceride accumulation, and stimu-
lates fatty acid oxidation and glucose
uptake in myocytes (Yamauchi et al.,
2002).
Healthy volunteers who perceived
their skin to be ‘sensitive’ or ‘non-
sensitive’ were recruited. Sensitive skin
individuals were identiﬁed based on
questionnaires and a 10% lactic acid
stinging test as previously described
(Farage and Maibach, 2010; Kim et al.,
2014). Those with underlying skin
diseases such as atopic dermatitis,
contact dermatitis, and rosacea were
excluded. This study was approved by
the Institutional Review Board at Seoul
National University Hospital and con-
ducted according to the Declaration of
Helsinki. All subjects provided written
informed consent. We found that
the expression of ADIPOQ mRNA
(Figure 1a) and protein (Figures 1b
and c, as shown by Western blot
and immunoﬂuorescence staining,
respectively) was markedly downregu-
lated in sensitive skin tissues, in com-
parison with non-sensitive skin tissues.
ADIPOQ binds to ADIPOQ receptor 1
(ADIPOR1) and ADIPOQ receptor 2
(ADIPOR2) and activates 5′-AMP-acti-
vated protein kinase (AMPK). AMPK is a
master regulator of glucose and lipid
metabolism and is activated by various
cellular stresses, physiologic stimuli
such as muscle contraction, and hor-
mones such as ADIPOQ (Hardie et al.,
2006; Ruderman et al., 2013). ADIPOQ
regulates peripheral and whole-body
energy metabolism via controlling
AMPK activity (Sattar and Sattar,
2012). Expression of ADIPOR1/2 was
reduced in sensitive skin (Figure 1d). In
addition, the level of phospho-AMPK
was markedly decreased in sensitive
skin tissues, whereas the total AMPK
level remained unchanged (Figure 1e).
These results suggest that decreased
expression of ADIPOQ and its recep-
tors, accompanied by low AMPK activ-
ity, is implicated in the development of
sensitive skin.
To examine the contributory role of
ADIPOQ in the pathogenesis of sensi-
tive skin, we performed small interfering
RNA (siRNA)-mediated knockdown of
the ADIPOQ gene in vitro. Our previous
in vivo results obtained in sensitive skin
tissues suggest that decreased synthesis
of ATP and lower pH cause abnormal
muscle contraction and skin sensitivity
(Kim et al., 2014). Thus, we examined
transcript and physiologic changes in
human rhabdomyosarcoma (RD) cells,
as an in vitro model of human skeletal
muscle, transfected with ADIPOQ
siRNA. Intriguingly, transient transfec-
tion of ADIPOQ siRNA into RD cells
recapitulated the distinct gene express-
ion signature related to muscle
composition, carbohydrate and lipid
metabolism, and ion balance
(Figure 2a), as previously described in
human sensitive skin in vivo (Kim et al.,
2014). ATP amount was also
signiﬁcantly decreased in ADIPOQ
siRNA–treated RD cells as measured
using the ENLITEN ATP Assay System
Bioluminescence Detection Kit
(Promega, Madison, WI; Figure 2b). To
measure intracellular pH, cells were
incubated with 4 μM BCECF AMAccepted article preview online 16 April 2015; published online 14 May 2015
Abbreviations: ADIPOQ, adiponectin; ADIPOR, adiponectin receptor; AMPK, 5′-AMP-activated
protein kinase; ASIC3, acid sensing ion channel 3; CGRP, calcitonin gene–related peptide; RD,
rhabdomyosarcoma; siRNA, small interfering RNA; TRPV1, transient receptor potential cation channel
subfamily V member 1
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